Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Rab Proteins01:14

Rab Proteins

Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

4 Phenylbutyrate Plus Gene augmentation: A Dual Therapy To Rescue of SLC6A1 Variant Associated Developmental And Epileptic Encephalopathy.

bioRxiv : the preprint server for biology·2026
Same author

4-Phenylbutyrate Rescue in <i>GABRA1</i> Variants Associated with Developmental Epileptic Encephalopathies: from Cell and Mouse Models to Human.

bioRxiv : the preprint server for biology·2026
Same author

Unraveling 4-Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition.

Annals of clinical and translational neurology·2026
Same author

Artificial intelligence in the assessment of epilepsy-related genetic mutations: Learned from GABA<sub>A</sub> receptors and GABA transporter 1.

Epilepsia open·2026
Same author

Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification.

medRxiv : the preprint server for health sciences·2026
Same author

Accumulation of Extracellular GABA, Impaired GABAergic Neurotransmission and 4-Phenylbutyrate Rescue in Mice of <i>SLC6A1</i> Variant-Mediated Disorders.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 11, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Trafficking-deficient mutant GABRG2 subunit amount may modify epilepsy phenotype.

Jing-Qiong Kang1, Wangzhen Shen, Robert L Macdonald

  • 1Departments of Neurology, Vanderbilt University Medical Center, Nashville, TN.

Annals of Neurology
|May 31, 2013
PubMed
Summary

Nonsense mutations in GABRG2 genes cause epilepsy by producing truncated proteins. Differences in how these proteins are metabolized and affect GABA-A receptor function contribute to epilepsy severity and genetic disease variability.

More Related Videos

Neurocircuit Assays for Seizures in Epilepsy Mutants of Drosophila
09:11

Neurocircuit Assays for Seizures in Epilepsy Mutants of Drosophila

Published on: April 15, 2009

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Related Experiment Videos

Last Updated: May 11, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Neurocircuit Assays for Seizures in Epilepsy Mutants of Drosophila
09:11

Neurocircuit Assays for Seizures in Epilepsy Mutants of Drosophila

Published on: April 15, 2009

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Area of Science:

  • Neurogenetics
  • Molecular Biology
  • Cellular Biology

Background:

  • Genetic epilepsies and other inherited diseases often show variable severity (phenotypic heterogeneity) due to unknown factors.
  • Nonsense mutations can lead to truncated proteins, with severity influenced by nonsense-mediated mRNA decay (NMD) efficiency.
  • Mutations in the last exon may evade NMD, producing full-length truncated proteins.

Purpose of the Study:

  • To compare the effects of truncated γ2 subunits from GABRG2 nonsense mutations on epilepsy of varying severity.
  • To investigate the impact of these truncated subunits on channel biogenesis, function, and cellular homeostasis.
  • To analyze the role of mutation location, specifically last-exon mutations, on protein metabolism and disease presentation.

Main Methods:

  • Coexpression of GABA-A receptor subunits in non-neuronal cells and neurons.
  • NMD assessment using minigenes.
  • Protein degradation rates via (35)S radiolabeling.
  • Channel function evaluation through whole-cell recordings.
  • Subunit trafficking, cellular toxicity, polyubiquitination, and ER stress analysis using flow cytometry, immunoblotting, and immunohistochemistry.

Main Results:

  • All GABRG2 nonsense mutations led to reduced γ2 subunit surface expression.
  • Truncated subunits exhibited differential degradation rates, stabilities, and polyubiquitin conjugation.
  • Mutant subunits suppressed wild-type subunit biogenesis and function, increasing endoplasmic reticulum stress.

Conclusions:

  • Each GABRG2 nonsense mutation generates distinct intracellular levels of trafficking-deficient γ2 subunits.
  • Metabolic differences in mutant subunits contribute to varying degrees of wild-type channel suppression and cellular disturbance.
  • These molecular variations likely underlie epilepsy severity and contribute to phenotypic heterogeneity in inherited human diseases.